Rebif market forecast sees MS demand, aging populations drive growth

The Business Research Company says the global Rebif market is set to expand through 2035 as multiple sclerosis diagnoses rise, older populations grow and at-home injectable treatment demand increases. North America is projected to lead the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Rebif is a disease-modifying therapy used to manage multiple sclerosis, a chronic condition that affects the central nervous system. - The market outlook points to continued demand for MS treatments as diagnosis rates rise and long-term disease management becomes more important. - The forecast also highlights a shift toward personalized care and home-based injectable treatment options.

What happened: - The Business Research Company published its Rebif Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the Rebif market has grown on the back of rising MS diagnoses, wider use of interferon-based treatments, more neurologic specialty care, stronger relapse-prevention awareness and broader access to injectable therapies. - The report forecasts further growth through 2035. - The company published a free sample of the report. - The company also posted the full market report.

The details: - Rebif is an interferon that modulates the immune system and reduces inflammation in the central nervous system. - The therapy helps protect the myelin sheath around nerve fibers, lowering relapse rates and slowing disease progression. - The report identifies rising global MS prevalence as a major market driver. - NHS England reported in July 2024 that MS affects more than 150,000 people in the UK, including more than 120,000 in England. - NHS England also said about 135 new diagnoses occur each week, with women more affected than men. - The report says the aging population is another growth driver because older adults are more likely to live with MS and need ongoing disease management. - The Population Reference Bureau said in January 2024 that the U.S. population age 65 and older is expected to rise from 58 million, or 17% of the population, in 2022 to 82 million, or 23%, by 2050. - The report says higher healthcare spending is also supporting Rebif demand by improving access to treatment. - OECD data put average healthcare spending in member countries at about $6,000 per person in 2024, adjusted for purchasing power. - The report expects greater use of disease-modifying therapies, wider adoption of injectable interferon options, earlier MS intervention, longer-term care protocols and stronger adherence strategies. - North America is projected to hold the largest Rebif market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The forecast suggests Rebif is benefiting from two parallel trends: more people being diagnosed with MS and a treatment model that increasingly favors continued, long-term management. - North America’s lead reflects established healthcare systems and better access to advanced MS therapies. - Faster growth in Asia-Pacific points to improving healthcare infrastructure and broader diagnosis of chronic neurological disease. - The report’s focus on specialty pharmacies and home injection suggests distribution and convenience are becoming more important in MS care.

What's next: - The report expects demand to keep rising as MS treatment plans become more personalized and patients shift toward therapies that can be used at home. - Specialty pharmacy distribution is likely to play a larger role in how Rebif reaches patients. - Investment in next-generation MS treatments could reshape the competitive landscape over time. - The Business Research Company says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards, hotspot infographics and updated trend graphics.

The bottom line: - Rebif’s outlook is tied to a larger MS treatment market that is expanding as diagnoses rise, populations age and care moves toward longer-term, more convenient therapy models.